

Peter J Grant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1660304/publications.pdf>

Version: 2024-02-01

68
papers

7,307
citations

126858

33
h-index

123376

61
g-index

70
all docs

70
docs citations

70
times ranked

8897
citing authors

#	ARTICLE	IF	CITATIONS
1	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
2	Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1792-1801.	13.9	745
3	Circadian Rhythm and Sleep Disruption: Causes, Metabolic Consequences, and Countermeasures. <i>Endocrine Reviews</i> , 2016, 37, 584-608.	8.9	423
4	Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. <i>Blood</i> , 2002, 100, 743-754.	0.6	322
5	The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. <i>Blood</i> , 2000, 96, 988-995.	0.6	314
6	Association of a Common Polymorphism in the Factor XIII Gene with Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 1998, 79, 8-13.	1.8	276
7	The genetics of haemostasis: a twin study. <i>Lancet</i> , The, 2001, 357, 101-105.	6.3	266
8	Effects of Novel Polymorphisms in the RAGE Gene on Transcriptional Regulation and Their Association With Diabetic Retinopathy. <i>Diabetes</i> , 2001, 50, 1505-1511.	0.3	220
9	Association of a Common Polymorphism in the Factor XIII Gene With Venous Thrombosis. <i>Blood</i> , 1999, 93, 906-908.	0.6	210
10	Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. <i>Lancet</i> , The, 2003, 361, 1424-1431.	6.3	187
11	Altered Fibrin Clot Structure in the Healthy Relatives of Patients With Premature Coronary Artery Disease. <i>Circulation</i> , 2002, 106, 1938-1942.	1.6	172
12	The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2019, 40, 3215-3217.	1.0	132
13	The molecular physiology and pathology of fibrin structure/function. <i>Blood Reviews</i> , 2005, 19, 275-288.	2.8	126
14	Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus. <i>Thrombosis and Haemostasis</i> , 1995, 74, 842-847.	1.8	125
15	Functional Analysis of the Fibrinogen A α Thr312Ala Polymorphism. <i>Circulation</i> , 2003, 107, 2326-2330.	1.6	120
16	Factor V Leiden Gene Mutation and Thrombin Generation in Relation to the Development of Acute Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 783-785.	1.1	119
17	Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. <i>FASEB Journal</i> , 2000, 14, 791-796.	0.2	113
18	A α -Fibrinogen Thr312Ala polymorphism and venous thromboembolism. <i>Blood</i> , 2000, 96, 1177-1179.	0.6	112

#	ARTICLE	IF	CITATIONS
19	Association of the ϵ -Fibrinogen Thr312Ala Polymorphism With Poststroke Mortality in Subjects With Atrial Fibrillation. <i>Circulation</i> , 1999, 99, 2423-2426.	1.6	108
20	Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. <i>Lancet</i> , The, 2002, 359, 667-671.	6.3	103
21	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 46-52.	5.5	103
22	von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease. <i>Thrombosis and Haemostasis</i> , 1997, 77, 1104-1108.	1.8	103
23	Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Promoter Polymorphism and Levels in Subjects with Cerebrovascular Disease. <i>Thrombosis and Haemostasis</i> , 1997, 77, 730-734.	1.8	100
24	The Effect of Dimethylbiguanide on Thrombin Activity, FXIII Activation, Fibrin Polymerization, and Fibrin Clot Formation. <i>Diabetes</i> , 2002, 51, 189-197.	0.3	90
25	Circulating Levels of Factor VII, Fibrinogen, and von Willebrand Factor and Features of Insulin Resistance in First-Degree Relatives of Patients With NIDDM. <i>Circulation</i> , 1996, 94, 2171-2176.	1.6	89
26	Coagulation and atherothrombotic disease. <i>Atherosclerosis</i> , 2006, 186, 240-259.	0.4	81
27	Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. <i>Blood</i> , 2013, 122, 134-142.	0.6	79
28	Gender-Specific Associations of the Fibrinogen B β 448 Polymorphism, Fibrinogen Levels, and Acute Cerebrovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 589-594.	1.1	65
29	Genetics of fibrin clot structure: a twin study. <i>Blood</i> , 2004, 103, 1735-1740.	0.6	59
30	Role of IGF-1 in glucose regulation and cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 1135-1149.	0.6	51
31	Factor VII Gene Polymorphisms, Factor VII:C Levels and Features of Insulin Resistance in Non-Insulin-Dependent Diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 1996, 75, 401-406.	1.8	47
32	Cre/lox Studies Identify Resident Macrophages as the Major Source of Circulating Coagulation Factor XIII-A. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1494-1502.	1.1	44
33	PAI-1 Concentrations in First-degree Relatives of Patients with Non-insulin-dependent Diabetes: Metabolic and Genetic Associations. <i>Thrombosis and Haemostasis</i> , 1997, 77, 357-361.	1.8	40
34	Selective Enhancement of Insulin Sensitivity in the Endothelium In Vivo Reveals a Novel Proatherosclerotic Signaling Loop. <i>Circulation Research</i> , 2017, 120, 784-798.	2.0	33
35	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	1.0	32
36	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. <i>Cardiovascular Diabetology</i> , 2020, 19, 3.	2.7	31

#	ARTICLE	IF	CITATIONS
37	Association of Factor VII:C Levels with Environmental and Genetic Factors in Patients with Ischaemic Heart Disease and Coronary Atheroma Characterised by Angiography. <i>Thrombosis and Haemostasis</i> , 1996, 76, 161-165.	1.8	29
38	The cardiovascular safety of rosiglitazone. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 367-376.	1.0	28
39	Interaction between Insulin Resistance and Factor XIII Val34Leu in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1202-1203.	1.8	26
40	Genetic determinants of arterial thrombosis. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 505-532.	0.7	24
41	Alterations in Rev-ERB β /BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study. <i>Acta Diabetologica</i> , 2021, 58, 1111-1117.	1.2	22
42	Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092058.	0.9	18
43	Normal Bone Deposition Occurs in Mice Deficient in Factor XIII-A and Transglutaminase 2. <i>Matrix Biology</i> , 2015, 43, 85-96.	1.5	16
44	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
45	(Δ) cis-bisamido epoxides: A novel series of potent FXIII-A inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 98, 49-53.	2.6	13
46	Diabetes and coronary artery disease: not just a risk factor. <i>Heart</i> , 2020, 106, 1357-1364.	1.2	13
47	Light therapy improves diurnal blood pressure control in night shift workers via reduction of catecholamines: the EuRhythDia study. <i>Journal of Hypertension</i> , 2021, 39, 1678-1688.	0.3	11
48	PCR-RFLP Detection of PAI-2 Gene Variants: Prevalence in Ethnic Groups and Disease Relationship in patients Undergoing coronary Angiography. <i>Thrombosis and Haemostasis</i> , 1997, 77, 0955-0958.	1.8	11
49	Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 1047-1059.	0.6	10
50	Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 98-112.	0.9	10
51	Transglutaminase 2 limits the extravasation and the resultant myocardial fibrosis associated with factor XIII-A deficiency. <i>Atherosclerosis</i> , 2020, 294, 1-9.	0.4	10
52	Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 329-330.	1.0	10
53	Association of a Common Polymorphism in the Factor XIII Gene With Venous Thrombosis. <i>Blood</i> , 1999, 93, 906-908.	0.6	10
54	Timed physical exercise does not influence circadian rhythms and glucose tolerance in rotating night shift workers: The EuRhythDia study. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095061.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Incidence of Arg506 → Gln Mutation (Factor V Leiden) in Pima Indians. <i>Thrombosis and Haemostasis</i> , 1997, 78, 961-962.	1.8	6
56	Use of a novel floxed mouse to characterise the cellular source of plasma coagulation FXIII-A. <i>Lancet</i> , The, 2015, 385, S39.	6.3	5
57	Myocardial dysfunction in diabetes: Another epidemic?. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 319-320.	0.9	4
58	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 139-140.	5.5	3
59	±-Fibrinogen Thr312Ala polymorphism and venous thromboembolism. <i>Blood</i> , 2000, 96, 1177-1179.	0.6	2
60	A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. <i>Cardiovascular Diabetology</i> , 2021, 20, 238.	2.7	2
61	Commingling analysis of the distribution of a phenotype conditioned on two marker genotypes: Application to plasma angiotensin-converting enzyme levels. , 1996, 13, 615-625.		1
62	Abnormalities in thrombotic pathways in diabetes: A tale of two platelets. <i>Journal of Diabetes</i> , 2018, 10, 793-795.	0.8	1
63	Rosiglitazone and cardiovascular disease: a diabetologist's perspective. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, 75-76.	0.9	0
64	Does genetic variation in the <i>Clock</i> gene impact obesity and the metabolic syndrome?. <i>Aging Health</i> , 2008, 4, 101-103.	0.3	0
65	London buses: A cardiovascular outcome trial equivalent?. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 382-383.	0.9	0
66	PCSK9 inhibitors- A new age in lipid management?. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 171-171.	0.9	0
67	Diabetes and cardiovascular disease: it's time to apply the evidence. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 586-588.	0.4	0
68	Prescribing Paradigm Shift? Damned If You Do, Damned If You Don't. <i>Diabetes Care</i> , 2020, 43, 1991-1993.	4.3	0